Integrated Genome Engineering Platforms

Demeetra delivers industry‑leading genome engineering for commercial bioprocessing and discovery research, enabling everything from targeted edits to stable expression.

Talk to an Expert
Explore Technologies
Our BPI 2025 Webcast Now On Demand. Watch the full recorded session and Q&A. Click Here!

Demeetra provides freedom to operate in biologics manufacturing through versatile IP portfolios and expert technology transfer from R&D to production

Cas-CLOVER

The Clean Alternative to CRISPR with IP freedom, Cas-CLOVER executes highly specific genome edits, enabling complete gene knockouts and precise site-directed knock-ins.

CleanCut CHO Platform

Suspension CHO-K1 cells precisely engineered with Cas-CLOVER, optimized for high-performance bioprocessing and stable expression.

Hyperactive Super piggyBac

A non-viral transposase system enabling high-copy gene integration for disease modeling and cell therapy research, exclusively licensed by Demeetra following its acquisition of Hera BioLabs.

Harbor-IN

A license-free transposase designed for frictionless, high-titer commercial stable cell line development.

Put genome engineering platforms to the test with Demeetra technical support

Integrated Genome Engineering: The Demeetra Platform Advantage

Demeetra Platforms

Cas-CLOVER | CleanCut CHO | Super piggyBac | Harbor-IN

 Other Tools
Clear, purpose-built IP
 Encumbered or unclear IP
High precision
 Off-target effects
Discovery to production
 Limited scalability
Biopharma, CDMO, research reagents, discovery models & diagnostics
 Narrow or single-use applications
Streamlined with options
 Complex

Licensing & Purchasing Options

Demeetra offers multiple, flexible access paths aligned with how biotechnology companies build products from research through commercialization.

Licensed Platforms

Broad commercial access through platform licenses

Cas-CLOVER™
  • Targeted genome editing
  • Broad commercial rights
Super piggyBac
  • Supports cell & reagent discovery
  • Includes transposase mRNA

Product-Based Access

Product access with a clear path to commercial use

CleanCut™ CHO Platform
  • Product access with a commercial pathway
  • Supports GMP and commercialization
Harbor-IN™ Transposase
  • Stable cell line development
  • No platform license required

Why Licensing Matters

Demeetra licensing ensures clear freedom to operate and long-term support as programs move from research to commercial manufacturing.

Discovery → Development → GMP – Commercial Manufacturing

All access models are designed to support progression across the full lifecycle.

As Seen In Top Tier Publications

Our genome engineering technologies have been featured in leading publications.

Proven in Practice

Leading scientists are utilizing our platform to achieve precise and efficient results in real-world research.

“

Cas-CLOVER enhanced our CHO line protein expression with no observable off-target mutations.

Dr. Kayla Bean

Elanco

“

Cas-CLOVER enabled >90% STAT1 knockout in HEK293 cells used for rAAV production.

Takeda Pharmaceuticals, Inc.

Andorfer et al. 2024 Biotechnol. J.

“

Using the Super piggyBac transposon system, CAR transgenes can be stably integrated into primary T cells, enabling the generation of highly potent CAR-T cells.

Poseida Therapeutics, Inc.

Madison et al. 2022 Molecular Therapy Nucleic Acids.

Why Partner With Demeetra

We help biotech innovators accelerate discovery and scale production with technologies built for precision, efficiency, and freedom to operate

Freedom to Operate (FTO)

No entangling IP restrictions

Dual-use Technology

From research to production with the same cells & tools

Expert Support

Partnering with scientists and BD teams every step of the way

Proven Performance

Cas-CLOVER and CleanCut CHO already powering leading programs

Trusted By Leading Biotechnology Organizations

Elanco Logo
Poseida Therapeutics logo
Sanofi logo
AGC Biologics logo

Demeetra provides integrated genome engineering platforms, and products, backed by deep technical expertise.

Contact us to learn how our differentiated IP, flexible access models, and internal know-how can support adoption from discovery through bioprocessing and commercial use.

Buy Products
Schedule A Call